相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Landscape of Chromosome Instability in Breast Cancers and Associations with the Tumor Mutation Burden: An Analysis of Data from TCGA
Ioannis A. Voutsadakis
CANCER INVESTIGATION (2021)
Preanalytical Variables for the Genomic Assessment of the Cellular and Acellular Fractions of the Liquid Biopsy in a Cohort of Breast Cancer Patients
Stephanie N. Shishido et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient
Lisa Welter et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2020)
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer
Pushpinder Kaur et al.
SCIENTIFIC REPORTS (2019)
PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study
Eleni Tzanikou et al.
MOLECULAR ONCOLOGY (2019)
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
Janakiraman Subramanian et al.
ONCOLOGIST (2019)
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Sarah Croessmann et al.
CLINICAL CANCER RESEARCH (2019)
Effect of Blood Collection Tube Type and Time to Processing on the Enumeration and High-Content Characterization of Circulating Tumor Cells Using the High-Definition Single-Cell Assay
Mariam Rodriguez-Lee et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
Luc Cabel et al.
Oncotarget (2018)
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JAMA ONCOLOGY (2018)
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
David M. Hyman et al.
NATURE (2018)
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
Emiliano Cocco et al.
SCIENCE SIGNALING (2018)
nCirculating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial
Costanza Paoletti et al.
CLINICAL CANCER RESEARCH (2018)
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Viktor A. Adalsteinsson et al.
NATURE COMMUNICATIONS (2017)
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer
Ariella B. Hanker et al.
CANCER DISCOVERY (2017)
Activating HER2 mutations as emerging targets in multiple solid cancers
Claire M. Connell et al.
ESMO OPEN (2017)
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2017)
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
Xiaowei Xu et al.
CLINICAL CANCER RESEARCH (2017)
Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States
Angela B. Mariotto et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2017)
HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers
Tonghui Wang et al.
CANCER SCIENCE (2017)
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4
Susan Breslin et al.
BRITISH JOURNAL OF CANCER (2017)
HER2 mutation status in Japanese HER2-positive breast cancer patients
Yumi Endo et al.
BREAST CANCER (2016)
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JAMA ONCOLOGY (2016)
Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).
Cynthia X. Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
8p deletion is strongly linked to poor prognosis in breast cancer
P. Lebok et al.
CANCER BIOLOGY & THERAPY (2015)
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok et al.
CLINICAL CANCER RESEARCH (2015)
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer
Christiane Daniela Fichter et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Circulating Tumor Microemboli Diagnostics for Patients with Non-Small-Cell Lung Cancer
Anders Carlsson et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
Claire Corcoran et al.
MOLECULAR CANCER (2014)
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Martina S. J. McDermott et al.
MOLECULAR CANCER (2014)
Rapid Phenotypic and Genomic Change in Response to Therapeutic Pressure in Prostate Cancer Inferred by High Content Analysis of Single Circulating Tumor Cells
Angel E. Dago et al.
PLOS ONE (2014)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
Genome-wide copy number analysis of single cells
Timour Baslan et al.
NATURE PROTOCOLS (2012)
Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers
Dena Marrinucci et al.
PHYSICAL BIOLOGY (2012)
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
Heidi Greulich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells
B. C. Browne et al.
ANNALS OF ONCOLOGY (2011)
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ
Nicole Saenger et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study
Michael Andersson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tumour evolution inferred by single-cell sequencing
Nicholas Navin et al.
NATURE (2011)
Inferring tumor progression from genomic heterogeneity
Nicholas Navin et al.
GENOME RESEARCH (2010)
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
Kwok-K. Wong et al.
CLINICAL CANCER RESEARCH (2009)
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
Prithviraj Bose et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
Daniel F. Hayes et al.
CLINICAL CANCER RESEARCH (2006)
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
SK Rabindran et al.
CANCER RESEARCH (2004)
Breast cancer in young women (≤35 years):: Genomic aberrations detected by comparative genomic hybridization
S Weber-Mangal et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer
BI Sigbjörnsdottir et al.
JOURNAL OF MEDICAL GENETICS (2000)
分享论文
